HIF1A and glioblastoma: Based on our previous research, we consider that the alginate–gelatin hydrogel scaffold developed in this study could represent a valuable resource for the forthcoming glioblastoma targeted EGFRvIII therapies, including immunotherapeutic-like conventional antibodies or VNAR single domain therapeutic carriers [73], as our hydrogel scaffold micrometric attributes emulate relevant GBM tumor features, including hypoxia, which could also prompt chemoresistance and radioresistance through HIF-1α expression.